Lilly
-
USA
Eli Lilly is ready for obesity pill approval from FDA
Every weekday, CNBC Investment Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap…
Read More » -
USA
Eli Lilly launches program to boost employer coverage of obesity drugs
Eli Lilly On Thursday, the U.S. launched a new program designed to help more employers cover obesity medications, aiming to…
Read More » -
USA
Eli Lilly launches Zepbound obesity drug pen with one month of doses
An Eli Lilly & Co. issued in the Brooklyn borough of New York on March 28, 2024. Zepbound injection pen.…
Read More » -
USA
Novo Nordisk stock falls as weight loss drug fails to beat Eli Lilly
Novo Nordisk The stock fell 15% on Monday after it said its next-generation weight-loss drug failed to meet its core…
Read More » -
USA
What signal Lilly sends by stockpiling GLP-1 obesity pills ahead of FDA approval
Every weekday, CNBC Investment Club with Jim Cramer publishes Homestretch, an actionable afternoon update just in time for the final…
Read More » -
USA
We’re raising our price target on Eli Lilly as the GLP-1 leader delivers
Eli Lilly’s fourth-quarter results beat Wall Street’s forecasts on Wednesday; The key GLP-1 drugs, Mounjaro for diabetes and Zepbound for…
Read More » -
USA
Eli Lilly (LLY) earnings Q4 2025
The logo of Eli Lilly and Company is displayed at a press conference on September 23, 2025 in Houston, Texas,…
Read More » -
USA
Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data
CNBC’s Jim Cramer said Friday that the stock market will be well positioned for a recovery next week if heavyweight…
Read More » -
USA
Eli Lilly CEO David Ricks talks Medicare coverage of obesity pills
Eli Lilly Upcoming Medicare coverage of obesity drugs could be a key catalyst for the company’s launch of its closely…
Read More » -
USA
Eli Lilly plans $3.5 billion Pennsylvania plant for obesity drugs
Eli Lilly President and CEO Dave Ricks speaks at a press conference on September 23, 2025 in Houston. Antranik Tavitian…
Read More »